COMPANY

Damora Therapeutics

HQ: Philadelphia, PA source · damoratx.com ↗

Keywords: neoplasms subcutaneous antibody monoclonal antibody Myeloproliferative Neoplasms DMR-001

Location: Philadelphia, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

2026-09 Trial start Phase 1: A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms source ↗

2030-06 (ESTIMATED) · Phase 1 · A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms · NCT07849231

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07849231	A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms	Phase 1	Recruiting	2026-09	2030-06 (estimated)